We are exploring new therapies for patients with early relapsed metastatic triple-negative breast cancer. The study aims to understand their safety and effectiveness compared to existing options.
Health conditions and diseases that the clinical trial is designed to study and treat.
This type of breast cancer does not have hormone receptors for estrogen or progesterone and is also negative for the HER2 protein, making it more challenging to treat. Patients may experience early relapse after initial treatments.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.